Riskpilot← Back to searchSign inGet full accessAffibody AB
ABActiveOrg 5566656913Scheeles Väg 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 200494 employees
Revenue 2024
SEK 23,5M
-88% vs 2023
EBITDA margin
-930.1%
-121% vs 2023
Equity ratio
-135.1%
Financial strength
Net profit 2024
SEK -216,9M
-114% vs 2023
| Revenue | SEK 23,5M | -88% |
| EBITDA | SEK -219M | -121% |
| Net profit | SEK -216,9M | -114% |
| Total assets | SEK 47,7M | -70% |
| Equity | SEK -64,4M | -212% |
| Employees | 94 | — |
Legal name
Affibody AB
Org number
5566656913
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 september 2004
Share capital
SEK 100 000
Employees
94 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att, direkt eller indirekt, bedriva forskning och utveckling inom bioteknologi, marknadsföra, sälja och licensiera produkter och forskningsresultat inom bioteknologi samt bedriva annan därmed förenlig verksamhet. Bolaget skall vidare kunna äga och handla med aktier och värdepapper.
Address
Scheeles Väg 2
Email
reception@affibody.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 100 369 | 106 039 | 309 048 | 121 078 | 284 712 | 226 647 | 191 799 | 23 545 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 438 | −9 390 | −68 508 | −131 587 | 46 096 | −212 165 | −139 409 | −119 805 | −99 099 | −218 985 |
| Depreciation & amort. | −0 | −0 | — | — | — | — | — | — | — | — |
| EBIT | 438 | −9 390 | −68 508 | −131 587 | 46 096 | −212 165 | −139 409 | −119 805 | −99 099 | −218 985 |
| Net financials | −200 | −53 | 33 | 70 | 1 871 | 341 | — | 41 | 733 | 2 059 |
| Profit before tax | 239 | −9 443 | −68 475 | −131 517 | 47 967 | −211 824 | −139 409 | −119 764 | −98 367 | −216 926 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −2 926 | −0 |
| Net profit | 239 | −9 443 | −68 475 | −131 517 | 47 967 | −211 824 | −139 409 | −119 764 | −101 293 | −216 926 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 81 446 | 183 908 | 106 630 | 146 852 | 337 871 | 143 524 | 242 891 | 90 051 | 161 271 | 47 717 |
| Equity | 43 455 | 34 062 | 15 587 | 84 069 | 132 036 | 93 212 | 148 536 | 53 772 | 57 479 | −64 447 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 437 | 0 | 0 | 0 |
| Short-term debt | 34 968 | 149 846 | 91 043 | 62 783 | 205 835 | 50 312 | 93 917 | 33 452 | 99 964 | 106 325 |
| Total debt | 34 968 | 149 846 | 91 043 | 62 783 | 205 835 | 50 312 | 94 354 | 33 452 | 99 964 | 106 325 |
EBITDA margin
-930.1%
This company
15.8%
Market median
-5987% vs market
20152024
Equity ratio
-135.1%
This company
38.2%
Market median
-454% vs market
20152024
Return on equity
-21692600000.0%
This company
18.4%
Market median
-117894565317% vs market
20152024
Net profit margin
-921.3%
This company
8.1%
Market median
-11474% vs market
20152024
Asset turnover
0.49×
This company
1.12×
Market median
-56% vs market
20152024
Debt / equity
1.74×
This company
0.62×
Market median
-181% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DO Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
AK Chief Auditor | Chief Auditor | 2021 | — | — |
JT Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Affibody Medical AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Patricia Industries II AB
Affibody AB Board members of Affibody AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| David Olof Rikard Bejker | Chief Executive Officer | 0 companies |
| Anna Kristina Svanberg | Chief Auditor | 0 companies |
| Jakob Tomas Christoffer Grunditz | Chief Auditor | 0 companies |
| Anna Karin Nord | Deputy Board Member | 0 companies |
| Johan Gabriel Waltersson Stuart | Deputy Board Member | 0 companies |